RxDoctor Payments Data

Samantha Malave, MD

Family Medicine · Baytown, TXNPI 1972730349

Payments from drug & device makers

$3,046in general payments, 2019–2025

Across 170 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$524
  • Lilly USA, LLC$471
  • AstraZeneca$337
  • GSK$327
  • Boehringer Ingelheim$220
  • Exact Sciences$168
  • plus $999 from 22 others

What the payments were for

  • Food & beverage$3,046100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,046 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$66,533
Medicare patients
154
Services billed
1,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin161$130,723
OzempicSemaglutide98$119,447
EliquisApixaban118$98,227
FarxigaDapagliflozin Propanediol77$61,174
RybelsusSemaglutide23$38,799
MounjaroTirzepatide18$21,185
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$19,631
JanuviaSitagliptin Phosphate15$18,021
LinzessLinaclotide22$15,324
Breo ElliptaFluticasone/Vilanterol15$9,484
KerendiaFinerenone13$8,766
VascepaIcosapent Ethyl21$7,565
Tresiba Flextouch U-100Insulin Degludec18$7,321
TradjentaLinagliptin11$6,868
Rosuvastatin Calcium251$4,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$524$158,246121 claims
Boehringer IngelheimJardiance, Tradjenta$220$137,592172 claims
PfizerEliquis$83$98,227118 claims
AstraZenecaFarxiga$337$61,17477 claims
GSKTrelegy Ellipta, Breo Ellipta$327$29,11642 claims
Lilly USA, LLCMounjaro$471$21,18518 claims
MerckJanuvia$35$18,02115 claims
AbbVieLinzess$48$15,32422 claims
BayerKerendia$103$8,76613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Baytown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →